United States Orthobiologics Market Insights Forecasts to 2033

• The Market Size is Growing at a CAGR of 3.49% from 2023 to 2033
• The U.S. Orthobiologics Market Size is Expected to Hold a Significant Share by 2033

The U.S. Orthobiologics Market Size is Anticipated to Hold a Significant Share by 2033, Growing at a CAGR of 3.49% from 2023 to 2033.

Market Overview

Orthobiologics and regenerative medicine are often composed of substances that occur naturally in the body and are meant to promote accelerated healing from injuries. These products are used in orthopedic procedures to advance healing from bone fractures, muscles, ligaments, and tendons. Some of the largest reasons for orthobiologics usage are rising trends for a number of diseases affecting bones, such as bone neoplasms (malignant and benign) and osteomyelitis - bone infections. Besides these, there are hundreds of other incidents and medical situations where biologics injections are called for. Among them are various traumas - complex and simple; lesions in bones, as well as fractures. In these situations, orthopedic biologic products function as the best solution for the treatment of bone defects thus contributing to the advancement of the global market. Besides, the growing use of allografts based on the basis of a stem cell in the manifold procedures of orthopedics and other influences is expected to boost the market in the ensuing forecast period.

Report Coverage

This research report categorizes the market for the US orthobiologics market based on various segments and regions forecasts revenue growth and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the United States orthobiologics market. Recent market developments and competitive strategies such as expansion, product launch, and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the U.S. orthobiologics market.

Driving Factors

The growing incidence of orthopedic injuries and musculoskeletal diseases, accompanied by excruciating physical pain and limited mobility, represents one of the major drivers that will spur the demand for orthobiologics products during the forecast period. For instance, more than 6.8 million patients with orthopedic injuries receive medical attention in the U.S. alone every year, according to the statistics of the American Academy of Orthopaedic Surgeons. Such a massive patient pool requiring treatment for injuries related to orthopedics will likely contribute to the growth of the orthobiologics market over the next couple of years.

Restraining Factors

Bone graft substitutes are connected with a number of clinical limitations including adverse tissue reaction, incomplete or absence of bone formation, and infection of soft tissue & bone. Such drawbacks are anticipated to negatively influence the demand for orthobiologics products in the forecast period.

Market Segmentation

The US orthobiologics market share is classified into product type and application.

• The viscosupplements segment is expected to hold a significant market share through the forecast period.

The United States orthobiologics market is segmented by product type into viscosupplements, bone growth factors, demineralized bone matrix (DBM), synthetic bone substitutes, cellular allografts, allografts, and others. Among these, the viscosupplements segment is expected to hold a significant market share through the forecast period. This is attributed to the rapidly growing knee osteoarthritis and degenerative arthritis, especially among the growing geriatric population. Improvements in reimbursement policies concerning approvals on viscosupplements are further helping support the growth of this segment.

• The spinal fusion segment is expected to dominate the US orthobiologics market during the projected period.

Based on the application, the United States orthobiologics market is divided into spinal fusion, maxillofacial & dental, soft tissue repair, reconstructive & fracture surgery, and others. Among these, the spinal fusion segment is expected to dominate the US orthobiologics market during the projected period. This is attributed to the surge in spinal fusion surgeries performed. Along with this, massive companies with large orthobiologics product portfolios related to spinal fusion applications, along with rising approvals for new products for spinal fusion procedures, are expected to further spur growth in the segment in the near future.

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the United States orthobiologics market along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies

• Zimmer Biomet
• DePuy Synthes (Johnson & Johnson Services, Inc.)
• Stryker
• Anika Therapeutics, Inc.
• SeaSpine
• Bioventus
• RTI Surgical
• MTF Biologics
• Arthrex, Inc.
• Smith & Nephew
• Others

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting And Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Recent Developments

• In October 2023, Orthofix Medical Inc. recently announced full commercial launch besides gaining the 510(k) clearance for the product OsteoCove. It is the advanced bioactive synthetic graft, which can be used in a number of orthopedic and spinal procedures.

Market Segment

This study forecasts revenue at U.S., regional, and country levels from 2020 to 2033. Spherical Insights has segmented the United States orthobiologics market based on the below-mentioned segments:

United States Orthobiologics Market, By Product Type

• Viscosupplements
• Bone Growth Factors
• Demineralized Bone Matrix (DBM)
• Synthetic Bone Substitutes
• Cellular Allograft
• Allografts
• Others

United States Orthobiologics Market, By Application

• Spinal Fusion
• Maxillofacial & Dental
• Soft Tissue Repair
• Reconstructive & Fracture Surgery
• Others